Systematic Ambulatory ECG Monitoring Following TAVI (NCT07739316)
Systematic Ambulatory ECG Monitoring Following TAVI: A Prospective Randomized Trial.
🩺 Plain-English Summary (8th-Grade Level)
This multicenter, prospective, randomized superiority trial will evaluate whether systematic 14-day ambulatory ECG monitoring following hospital discharge after transcatheter aortic valve implantation (TAVI) reduces the risk of sudden death, symptomatic arrhythmic events, or stroke within 1 year compared with standard post-discharge care. Patients undergoing successful TAVI without permanent pacemaker implantation and presenting with at least one ECG conduction abnormality at hospital discharge will be randomized to receive either ambulatory ECG monitoring or standard follow-up. All participants will undergo routine clinical follow-up at 30 days and 1 year after TAVI.
Who can join: Review the eligibility criteria below.
Location: Institut universitaire de cardiologie et de pneumologie de Québec - UL — Québec, Quebec
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Institut universitaire de cardiologie et de pneumologie de Québec - UL — Québec, Quebec
📞 Contact the Study Coordinator
Phone: (418) 656-8711
Email: josep.rodes-cabau@criucpq.ulaval.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Aortic Stenosis
- PERIGON Pivotal Trial — Los Angeles, California
- ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement — Birmingham, Alabama
- PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis — Birmingham, Alabama
- Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study — Tucson, Arizona
- Application of TAVI at Experienced Interventional Cardiac Centers Without On-site Cardiac Surgery (ATLAS Study) — Edmonton, Alberta
Explore by condition: All Aortic Stenosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.